



Dynavax Names D. Kevin Kwok, Vice President and Chief Business Officer

BERKELEY, Calif., March 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of D. Kevin Kwok, Pharm.D., to the position of vice president and chief business officer.

"We are excited to have Kevin join our team," said Dino Dina, M.D., president and chief executive officer of Dynavax. "We expect him to play a key role in managing our existing relationships with UCB and Berna while we continue to develop our strategy to secure the commercial success of the products under development."

Dr. Kwok was most recently vice president for the transaction advisory group, Clearview Projects, where he was responsible for the start-up and client management of the San Francisco practice. He brings more than 18 years of diverse industry experience with both pharmaceutical and biotechnology companies in various commercial areas. Prior to Clearview Projects, Dr. Kwok directed global strategic marketing, business development and corporate development at SUGEN from 1997 to 2000. After its merger with Pharmacia, he led strategic marketing and brand management for the company's joint angiogenesis portfolio in oncology. Previously, he also has held various management positions in US and international marketing, sales, new business ventures and other areas at Bristol-Myers Squibb and the Upjohn Company. Dr. Kwok earned his Doctor of Pharmacy degree from the University of Michigan.

About Dynavax

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Note: This press release contains "forward looking statements" within the meaning of the federal securities laws. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Dynavax undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release except as required by law.

Source: Dynavax Technologies Corporation